Month: January 2022

General

Merck’s COVID pill is last choice for U.S. patients, global use varies

Published by
Reuters
By Deena Beasley (Reuters) - Merck & Co's new antiviral pill, once touted as a potential game changer for treating COVID-19, is the last choice among four available options for at-risk patients given its relatively low efficacy and potential safety issues, U.S. doctors, healthcare systems and pharmacies told Reuters. A rival oral treatment from Pfizer Inc, Paxlovid, is in high demand, followed by an intravenous antibody therapy made by GlaxoSmithKline and Vir Biotechnology. With supplies of those products tight, doctors facing a surge of cases caused by the Omicron variant are also turning to ...
Read More >
Government Policy

COVID-19: You can’t have a recovery using the same bad medicine

Published by
Global Voices
COVID-19 emergency response activities, Madartek, Basabo, Dhaka. Image via Flickr by UN Women Asia and The Pacific. CC BY-NC-ND 2.0. Jocelyn Modello, Nadeen Madkour and Siddharth Akali co-authored the post. We are beginning 2022 with the world reeling under rising Omicron cases. It has been two years-global-research-and-innovation-forum) since the World Health Organization declared the coronavirus a public health emergency of international concern. And we still have pressing questions around how we shepherd ourselves out of the pandemic, and through the recovery: Who will provide the funds? Wh...
Read More >